“Sarah brings an exceptional combination of clinical development leadership and regulatory expertise, particularly in advancing novel therapies for obesity, MASH and other cardiometabolic diseases,” stated Hyung Heon Kim, President and CEO. bit.ly/4jkFyJE $MTVA

MetaVia's recently appointed Chief Medical Officer, Sarah Browne, M.D., brings deep expertise in dual GLP-1/glucagon receptor agonist development, including the development of pemvidutide. Read more about her experience: bit.ly/4sblko4 $MTVA

MetaVia has appointed Sarah Browne, M.D., as Chief Medical Officer. Dr. Browne brings more than 20 years of experience in clinical development, regulatory science and medicine, with expertise in obesity, metabolic and liver diseases, including MASH. bit.ly/4jkFyJE $MTVA

GLP-1 therapies have fundamentally reshaped obesity care and opened the door to a new era of combination therapies. But what comes next? GLP-1s have reshaped obesity care and opened the door to a new era of combination therapies. But what comes next? In an article for @TheScientistLLC, $MTVA CMO Chris Fang, MD, explores how complementary therapies could address the broader complexity of obesity. bit.ly/4gL1wUm

What’s next for obesity treatment beyond GLP-1s? In a new @TheScientistLLC article, MetaVia CMO Chris Fang, MD, explores how combination therapies could deliver broader metabolic benefits beyond weight loss. MetaVia’s preclinical research with vanoglipel highlights this potential across weight loss, glucose control, and liver health. Read the full article here: bit.ly/4gL1wUm

“We believe these findings provide important mechanistic support for the differentiated profile we continue to observe with DA-1726,” stated Hyung Heon Kim, President and Chief Executive Officer of MetaVia. Read more on the findings: bit.ly/46NAYfi $MTVA

MetaVia's DA-1726 tissue distribution study showed highest exposure in adipose (fat) tissue, with prolonged retention consistent with once-weekly dosing. These findings provide additional mechanistic support for the differentiated profile of DA-1726. bit.ly/46NAYfi $MTVA

MetaVia today announced preclinical tissue distribution results showing DA-1726-derived radioactivity is slowly absorbed and extensively distributed throughout the body after subcutaneous administration, with highest distribution seen in adipose tissue. bit.ly/46NAYfi $MTVA

MetaVia continues to advance DA-1726, with all active patients successfully reaching the highest planned dose levels of 48 mg and 64 mg in the ongoing Phase 1 Part 3 study of DA-1726, with 16-week topline data expected in the fourth quarter of 2026. bit.ly/4pZV3bd $MTVA

“During the second quarter of 2026, and subsequently, we continued to execute across both of our clinical development programs while further strengthening the differentiated profile of DA-1726 as a dual GLP-1/glucagon receptor agonist,” said H.H. Kim, CEO. bit.ly/4pZV3bd $MTVA

MetaVia today announced financial results for the second quarter ended June 30, 2026, and provided a corporate strategic update. For the full results and anticipated milestones, visit: bit.ly/4pZV3bd $MTVA

How can next-generation obesity therapies build on today's GLP-1 medicines? In a recent interview with @LongevityTech, MetaVia CEO Hyung Heon Kim discusses DA-1726, our development strategy, and the importance of balancing efficacy with tolerability. bit.ly/4xaamjU $MTVA

MetaVia today announced that all enrolled active patients in Part 3 of its Ph. 1 clinical trial evaluating DA-1726 for treatment of obesity have successfully completed dose titration and are now receiving the highest target doses in both study cohorts. bit.ly/3SHm5HT $MTVA

Tune-in tomorrow, June 24th at 10:30 am ET for MetaVia CEO Hyung Heon Kim's fireside chat highlighting the company's pipeline of novel obesity and metabolic therapies at the Life Sciences Virtual Investor Forum: bit.ly/4uCbCKR $MTVA

MetaVia today announced that Hyung Heon Kim, President and CEO, will participate in a fireside chat highlighting the company's pipeline of novel obesity and metabolic therapies at the Life Sciences Virtual Investor Forum on Wednesday, June 24th at 10:30 am ET. bit.ly/4a7IS5l $MTVA

At #ADA2026, MetaVia shared new data supporting the potential of its next-generation obesity and metabolic disease pipeline, showing its obesity therapies could offer broader benefits than weight loss alone. Read more on @DDWJournal : bit.ly/3S8XD1C $MTVA

Hyung Heon Kim, President and CEO of MetaVia, comments on the new late-breaking ADA 2026 data further reinforcing the differentiated and complementary potential of the Company's cardiometabolic pipeline: bit.ly/4oyGL0B $MTVA

Vanoglipel combined with resmetirom showed synergistic hepatoprotective and weight-loss effects in a preclinical MASH model, while vanoglipel with metformin saw enhanced glycemic control and weight reduction vs. monotherapy in preclinical T2D model. bit.ly/4oyGL0B $MTVA

The DA-1726 Ph. 1, 48 mg cohort achieved up to 9.1% mean body weight reduction at Day 54 without evidence of plateau, with consistent reductions in waist circumference and BMI in a once-weekly regimen without titration. Read more: bit.ly/4oyGL0B #ADA2026 $MTVA

MetaVia today announced the presentation of new late-breaking data highlighting its obesity and metabolic disease portfolio at the #ADA2026 Scientific Sessions, held June 5–8 in New Orleans, Louisiana. Read more: bit.ly/4oyGL0B $MTVA